Related Experiment Videos
Effects of converting enzyme inhibition on baroreflex sensitivity in patients with myocardial infarction
D Bonaduce1, M Petretta, G Morgano
1Institute of Internal Medicine, 2nd School of Medicine, Naples, Italy.
Insights
Captopril significantly improves baroreflex sensitivity in patients recovering from myocardial infarction. This finding suggests angiotensin-converting enzyme inhibition enhances the chronotropic response to baroreceptor stimulation, offering prognostic value.
Area of Science:
- Cardiology
- Pharmacology
- Physiology
Background:
- Baroreflex sensitivity is a key prognostic indicator post-myocardial infarction.
- The impact of angiotensin-converting enzyme (ACE) inhibition on baroreflex sensitivity remains uninvestigated in this patient population.
Purpose of the Study:
- To assess the effect of ACE inhibition with captopril on baroreflex sensitivity in patients with uncomplicated myocardial infarction.
Main Methods:
- Twenty-five post-myocardial infarction patients received captopril for 4 days, with baroreflex sensitivity measured before and after treatment.
- A control group of 20 patients received a placebo to account for spontaneous variations.
- Baroreflex sensitivity was quantified by the linear relationship between phenylephrine-induced blood pressure changes and RR interval variations.
Main Results:
- Captopril administration significantly increased mean baroreflex sensitivity (6.5 to 11.8 ms/mm Hg, p<0.01).
- 68% of patients showed an improvement greater than 2 ms/mm Hg.
- Plasma renin activity also increased significantly post-captopril, while remaining stable in the placebo group.
Conclusions:
- Captopril treatment significantly enhances baroreflex sensitivity in patients post-myocardial infarction.
- ACE inhibition improves the chronotropic response to baroreceptor stimulation.
- Findings suggest potential prognostic benefits of ACE inhibitors in myocardial infarction recovery.
Background:
Baroreflex sensitivity provides useful prognostic information in patients after acute myocardial infarction. However, no data are available about the effects of converting enzyme inhibition on this variable.
Objectives:
The aim of the study was to evaluate the effects of angiotensin-converting enzyme inhibition on baroreflex sensitivity in patients after uncomplicated myocardial infarction.
Methods:
Twenty-five patients after uncomplicated myocardial infarction underwent baroreflex sensitivity evaluation 72 to 96 h after symptom onset and after 4 days of captopril therapy. Twenty additional patients with the same characteristics were evaluated at the same time intervals before and after placebo administration to identify spontaneous baroreflex sensitivity variations. Baroreflex sensitivity was assessed by calculating the regression line relating phenylephrine-induced increases in systolic blood pressure to the attendant changes in the RR interval.
Results:
The mean baroreflex sensitivity value increased after captopril administration from 6.5 +/- 4.2 to 11.8 +/- 6.1 ms/mm Hg (p less than 0.01) and in individual analyses increased by greater than 2 ms/mm Hg in 68% of patients. Mean plasma renin activity increased after captopril from 3.7 +/- 2.4 to 8.5 +/- 4.9 ng/ml per h (p less than 0.005). No difference was detectable in baroreflex sensitivity and plasma renin activity values according to the site of necrosis. In the control group, baroreflex sensitivity and plasma renin activity remained unchanged between the two studies.
Conclusions:
This study demonstrates that in patients with uncomplicated myocardial infarction, captopril significantly improves the chronotropic response to baroreceptor stimulation.